Mage Biologics has queued a Phase I study (NCT06363383) of the antibody candidate MB-001 in healthy volunteers. The company is using an antibody technology developed in Andersen' lab to make the antibody more effective.
Mage Biologics is an U.S.-based biotechnology company that was formed as a collaboration between the Swiss specialty pharma company Tillotts Pharma AG and the international venture capital firm TVM Capital Life Science.
Read the story in Medwatch (Norwegian only)
Relevant link (Norwegian only)